bluebird bio Inc at Goldman Sachs Global Healthcare Conference Transcript
All right. Well, thank you, everyone, for joining us. I'm Salveen Richter, one of the biotechnology analysts at Goldman Sachs, and we're pleased to have the bluebird bio team here with us. So we have Chip Baird, CFO; and Dave Davidson, Chief Medical Officer.
Questions & Answers
Maybe to start here. You hosted an Analyst Day recently where you laid out kind of the early stage, next-generation pipeline that's following through your late-stage pipeline of 4 drugs here. Could you just walk us through, as we think about the evolution of bluebird, what your core focuses is going to be. A lot of these programs that came out were mostly oncology related. So is that really the way you see yourself progressing more versus severe genetic diseases? And what are you most excited about with regard to these programs and technologies?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
